On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
|
|
- Dora Tucker
- 5 years ago
- Views:
Transcription
1 On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical Sciences, UBC
2 Presenter Disclosure Presenter s Name: Trana Hussaini I have no current or past relationships with commercial entities Speaking Fees for current program: I have received no speaker s fee for this learning activity
3 Commercial Support Disclosure This program has received no financial or in-kind support from any commercial or other organization
4 Learning Objectives By the end of this session the audience will be able to: List the currently available direct acting antiviral (DAA) regimens for the treatment of chronic hepatitis C infection Select an appropriate HCV treatment regimen based on a patient's HCV genotype, previous treatment history, renal function and the extent of baseline liver disease
5 % Diagnosed 80% Treated 65% Mortality
6 Global Prevalence of Hepatitis C Hepatology 2015; 61(1):77-87
7 Chronic Hepatitis C Is a Progressive Disease HCC Healthy Liver Hepatic fibrosis Cirrhosis Transplantation 20 to 30 Years Progressive hepatic fibrosis with few or no symptoms over decades Most patients remain asymptomatic until hepatic decompensation Gastroenterol Clin North Am 2015; 44(4): Google Images collage by T. Hussaini Death
8 Global Annual Mortality Globally, 1.34 million people died of hepatitis in 2015 WHO GLOBAL HEPATITIS REPORT,
9 2030 Hepatitis C Elimination is Possible because
10 Treatment Success 100% Evolution of HCV Therapy IFN 6m IFN 12m IFN/R 6m IFN/R 12 m PEG/R 12m PI/PEG/R New DAA Graphics by T. Hussaini
11 HCV Treatment Evolution DAAs PEG-IFN + RBV Sustained Virological Response (SVR)/Cure rates ~ <10% to 55% Prolonged treatment duration ++++ ADR Graphics by T. Hussaini ADR Adverse Drug Reaction; DAAs Direct Acting Antiviral Agents; RBV Ribavirin; PEG-IFN - Pegylated Interferon; SVR Sustained Virological Response
12 HCV Treatment Evolution DAAs PEG-IFN + RBV P/R + Protease Inhibitors (PI) SVR ~40-70% +++++ADR Prolonged treatment duration Genotype 1 only ADR Adverse Drug Reaction; DAAs Direct Acting Antiviral Agents; PEG-IFN - Pegylated Interferon; RBV Ribavirin; SVR Sustained Virological Response
13 HCV Treatment Evolution DAAs PEG-IFN + RBV Interferon Freedom! NS5B + NS5A P/R + Protease Inhibitors (PI) SVR ~90% (GT1) SVR ~40-70% 12 week course +++++ADR ADR Prolonged treatment duration GT3 Genotype 1 only CKD
14 HCV Treatment Evolution DAAs PEG-IFN + RBV NS5B + NS5A P/R + PI 2 SVR ~90% nd Generation DAAs (GT1) SVR ~40-70% SVR > 95% 12 week course Genotype 1 only Pangenotypic ADR Prolonged treatment GT3duration CKD +++++ADR Resistance/TE CKD
15 HCV Treatment Evolution DAAs PEG-IFN + RBV NS5B + NS5A P/R + Protease Inhibitors (PI) 2 SVR ~90% nd Generation (GT1) 3 rd Generation DAAs DAAs SVR ~40-70% SVR > 95% 12 week course SVR > 95% +++++ADR Pangenotypic ADR Pangenotypic Prolonged treatment GT3duration CKD Resistance/TE Genotype 1 only Resistance CKD TE Treatment Experienced
16 Direct-Acting Antiviral Agents C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS3/4A Protease Inhibitor (PI) Multigenotypic to pangenotypic coverage Low barrier to resistance Contraindicated in patients with decompensated cirrhosis (Child-Pugh Class B or C) Moderate to high potential for DDI; less with newer generation PIs NS5B Nucleos(t)ide Inhibitors (NI) BUVIR Pangenotypic coverage Sofosbuvir (2013) High barrier to resistance Renally eliminated -Not recommended in pts with mod-severe renal impairment CrCl < 30ml/min Low potential for DDIs Collage by T Hussaini PREVIR Simeprevir (2013) Paritaprevir/r (2014) Asunaprevir (2016) Grazoprevir (2016) Glecaprevir (2017) Voxilaprevir (2017) NS5A Inhibitors Multigenotypic to pangenotypic coverage Low barrier to resistance Low to moderate potential for DDIs - Acid reducing therapies decrease absorption ASAVIR Ledipasvir (2014) Ombitasvir (2014) Daclatasvir (2015) Elbasvir (2016) Velpatasvir (2016) Pibrentasvir (2017)
17 Factors Determining HCV Treatment Regimen Genotype 1a, 1b, 2, 3, 4, 5, 6 Treatment History Treatment naïve or experienced Treatment Regimen Hepatic Fibrosis Mild to Moderate Fibrosis vs. Cirrhosis Collage by T Hussaini
18 HCV DAA Regimens Regimen Component Classes Dosing Approved Genotypes Sofosbuvir + simeprevir Paritaprevir/RTV/ ombitasvir /dasabuvir Sofosbuvir + daclatasvir Sofosbuvir/ledipasvir Sofosbuvir/velpatasvir Grazoprevir/elbasvir Glecaprevir/pibrentasvir Sofosbuvir/velpatasvir/ voxilaprevir NS5B+ NS3/4A PI NS3/4A PI + NS5A inhibitor + NN-NS5B NS5B+ NS5A inhibitor NS5B+ NS5A inhibitor NS5B+ NS5A inhibitor NS3/4A PI+ NS5A inhibitor NS3/4A PI + NS5A inhibitor NS5B+ NS5A inhibitor + NS3/4A PI Simeprevir: 150 mg QD Sofosbuvir: 400 mg QD Paritaprevir/RTV/ombitas vir: 150/100/25 mg QD Dasabuvir: 250 mg BID Sofosbuvir: 400 mg QD Daclatasvir: 60 mg QD Sofosbuvir/ledipasvir: 400/90 mg QD Sofosbuvir/velpatasvir: 400/100 mg QD Grazoprevir/elbasvir: 100/50 mg QD Glecaprevir/pibrentasvir 300/120mg Sof/Vel/Vox: 400/100/100 mg QD 1, 4 1, 4 (PrO) 1, 3 1, 4, 5, 6 1, 2, 3, 4, 5, 6 1, 4 1, 2, 3, 4, 5, 6 1, 2, 3, 4, 5, 6
19 Ledipasvir(NS5A)/Sofosbuvir(NS5B) HARVONI RBV NS5B NS3 NS5A
20 Ledipasvir/Sofosbuvir Health Canada Approval Oct 2014 Indication - Indicated for the treatment of chronic HCV genotype 1, 4, 5, 6 in adults Not recommended when egfr <30ml/min Dosing: Sofosbuvir-ledipasvir (fixed dose 400 mg/90 mg) one tablet orally once daily, with or without food Adverse Effects (AE): Fatigue, headache Drug Interactions: SOF: P-gp, BCRP substrate - Rifampin, antiepileptics and St John s Wort LVD: P-gp, BCRP substrate & inhibitor. Also weak inhibitor of CYP3A4, 2C9 Acid reducing therapy (PPIs and H 2 blockers decrease exposure to LDV) Ledipasvir/Sofosbuvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
21 Concomitant Drug: Effect Comment Acid Reducing Agents: gastric ph ledipasvir. Ledipasvir/Sofosbuvir Antacids H2-receptor antagonists Proton-pump inhibitors Antiarrhythmics: amiodarone ledipasvir unknown Separate antacid and LDV/SOF administration by 4 hours Administer H2-blockers simultaneously with or 12 hours apart from LDV/SOF at a dose that does not exceed doses comparable to famotidine 40 mg twice daily Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be administered simultaneously with LDV/SOF under fasted conditions Coadministration may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with LDV/SOF is not recommended digoxin digoxin Therapeutic concentration monitoring of digoxin is recommended Anticonvulsants: carbamazepine phenytoin phenobarbital oxcarbazepine Antimycobacterials: rifabutin rifampin HMG-CoA Reductase Inhibitors: rosuvastatin ledipasvir sofosbuvir GS ledipasvir sofosbuvir rosuvastatin concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of LDV/SOF. Coadministration is not recommended. Coadministration is not recommended Coadministration of LDV/SOF with rosuvastatin is not recommended Ledipasvir/Sofosbuvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
22 Ledipasvir/Sofosbuvir Clinical Trials SIRIUS # (n=154) GT-1 TE Cirrhotics (P/R ± PI experienced) LDV/SOF + RBV 12 weeks 96% (74/77) LDV/SOF 24 weeks 97% (75/77) *NEJM 2014;370: ; +NEJM 2014;370: ; NEJM 2014;370: ; # Lancet Infect Dis.2015, 15 (4):
23 Current AASLD & IDSA Recommendations for HCV Treatment with Ledipasvir-Sofosbuvir Genotype 1 Patient Populations Treatment naïve with or without cirrhosis* Treatment Duration 8*-12 weeks Treatment experienced** without cirrhosis 12 weeks Treatment experienced** with cirrhosis 24 weeks OR 12 weeks + RBV *Consider treatment duration of 8 weeks in treatment-naïve patients without cirrhosis who have a pretreatment HCV RNA less than 6 million IU/mL **Treatment-experienced patients who have failed treatment with either (a) peginterferon alfa plus ribavirin or (b) HCV protease inhibitor plus peginterferon alfa plus ribavirin Weight based ribavirin dosing: 1000 mg per day for patients less than 75 kg and 1200 mg for those weighing at least 75 kg, divided and administered twice daily. The starting dosage and on-treatment dosage of ribavirin can be decreased based on hemoglobin and creatinine clearance. AASLD-IDSA. Updated 2017 Sep 21.
24 Sofosbuvir(NS5B)/Velpatasvir(NS5A) EPCLUSA Pangenotypic Coverage RBV NS5B NS5A NS3
25 Sofosbuvir/Velpatasvir Health Canada approved Jul 2016 Indication Indicated for the treatment of chronic HCV genotypes 1-6 in adults: - without cirrhosis or with compensated cirrhosis (Child-Pugh A) - with decompensated cirrhosis (Child-Pugh B and C) combined with ribavirin Not indicated in patients with advanced CKD Dosing: Sofosbuvir-Velpatasvir (fixed dose 400 mg/100 mg) one tablet orally once daily, with or without food Adverse Effects (AE): Headache, fatigue, and nausea Drug Interactions: SOF: substrate of BCRP, P-gp VEL: substrate of CYP2B6, CYP2C8 and CYP3A4, BCRP, P-gp, OATP1B1 inhibitor of P-gp, BCRP, OATP 1B1/B3 Sofosbuvir/Velpatasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
26 Sofosbuvir/Velpatasvir Clinical Trials STUDY PATIENTS REGIMEN SVR12 ASTRAL -1 N= 624 GT 1, 2, 4 6 TN, TE 19% cirrhotic SOF/VEL (N = 629) Placebo (N = 116) 12 weeks 99% ASTRAL -2 GT 2 TN, TE 14% cirrhotic ASTRAL -3 GT 3 TN, TE 29% cirrhotic SOF/VEL (N = 134) SOF/RBV (N = 132) 12 weeks SOF/VEL x 12 weeks (N = 277 ) SOF/RBV x 24 weeks (N = 275) 99% 94% 95% 80% ASTRAL - 4 GT 1 6 TN, TE CTP-B Cirrhosis SOF/VEL X 12 weeks (N= 90) SOF/VEL+RBV X 12 weeks (N = 87) SOF/VEL X 24 weeks (N = 90) 83% 94% 86% Astral-1: Feld JJ et al. NEJM 2015; 373: Astral-2,3: Foster GR et al. NEJM2015; 373: Astral-4: Curry MP et al. NEJM2015; 373:
27 Recommended Dosage Regimens and Durations for Sofosbuvir/Velpatasvir Patient Population Treatment Duration GT 1-6 patients Noncirrhotic or with compensated cirrhosis (Child-Pugh A) SOF/VEL 12 weeks GT 1-6 with decompensated cirrhosis (Child-Pugh B and C) SOF/VEL + RBV* 12 weeks *Weight based ribavirin dosing: 1000 mg per day for patients less than 75 kg and 1200 mg for those weighing at least 75 kg, divided and administered twice daily. The starting dosage and on-treatment dosage of ribavirin can be decreased based on hemoglobin and creatinine clearance. Sofosbuvir/Velpatasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
28 Grazoprevir(NS3/4A)/Elbasvir(NS5A) ZEPATIER Patients with advanced CKD NS5B NS3 RBV NS5A
29 Grazoprevir/Elbasvir Health Canada Approval Jan 2016 Indication - Indicated for the treatment of chronic HCV genotypes 1 or 4 Contraindicated in patients with decompensated cirrhosis Dosing: Elbasvir-Grazoprevir (fixed dose 50 mg/100 mg) One tablet orally once daily, with or without food Adverse Effects(AE): - Fatigue, headache, and nausea - Increase in ALT > 5x normal in 1% of subjects DI: EBR: substrate of CYP3A4 and P-gp - inhibitor of BCRP, P-gp GZR: substrates of CYP3A, OATP1B1/3, BCRP and P-gp - Inhibitor of CYP3A4 & BCRP Grazoprevir/Elbasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
30 Drug-Drug Interactions: Contraindications Drug Class Drug(s) within Class that are Contraindicated Comments Grazoprevir/Elbasvir Anticonvulsants Antimycobacterials Herbal Products HIV Medications HIV Medications Immunosuppressants Phenytoin Carbamazepine Rifampin St. John s Wort (Hypericum perforatum) Efavirenz Atazanavir Darunavir Lopinavir Saquinavir Tipranavir Cyclosporine Significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction. Significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction. Significant decreases in elbasvir and grazoprevir plasma concentrations caused by strong CYP3A induction. Significant decreases in elbasvir and grazoprevir plasma concentrations caused by CYP3A induction. May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition. May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition. Grazoprevir/Elbasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
31 Mechanism of Drug Interactions for Grazoprevir/Elbasvir GZR is a substrate of OATP1B drug transporters GZR and EBR are substrates of CYP3A and P-gp OATP1B inhibitors CYP3A or P-gp inducers Strong CYP3A inhibitors GZR EBR GZR EBR GZR Coadministration is contraindicated Coadministration is contraindicated Coadministration is not recommended Zepatier SmPC, Jan Slide Borrowed from Fiona Marra with Permission
32 Grazoprevir-Elbasvir Clinical Trials STUDY PATIENTS REGIMEN SVR12 C-EDGE TN GT 1, 4, 6 TN; 22% cirrhotic C-EDGE TE GT 1, 4, 6 TE; 35% cirrhotic C-SALVAGE GT 1 PI experienced 43% cirrhotics C-WORTHY GT 1 Cohort 1: TN Cirrhotics Cohort 2: TE (null responders) 35% cirrhotics GZR/EBV 12 weeks GZR/EBV ± RBV 12 or 16 WEEKS Single arm GZR/EBV + RBV 12 weeks Overall: 95% GT1a with RAS 58% Overall: 92-97% 96% RAS 91.7% Cirrhosis 94.1% GZR/EBV 12 Wks 97% 18 Wks 94% GZR/EBV + RBV 12 Wks 90% 18 Wks 97% GZR/EBV 12 Wks 91% 18 Wks 97% GZR/EBV + RBV 12 Wks 94% 18 Wks 100% Zeuzem Z, et al. Ann Intern Med 2015;163:1-13. Kwo P et al. EASL Abstract P0886. Lawitz, et al. Lancet 2015 Mar 21; 385(9973): ; Buti et al. Clin Infect Dis. 2016;62(1):32 6.
33 Grazoprevir-Elbasvir: Resistance Associated Substitutions (RAS) HCV GT1a and Impact of Baseline NS5A Polymorphisms on SVR12 NS5A Polymorphism Status EBR-GZR x 12 weeks SVR12% (n/n) EBR-GZR + RBV x 16 weeks SVR12% (n/n) Without baseline NS5A polymorphism (M28, Q30, L31, or Y93) 98% (441/450) 100% (49/49) With baseline NS5A polymorphism (M28*, Q30*, L31*, or Y93*) 70% (39/56) 100% (6/6) Grazoprevir/Elbasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
34 Recommended Dosage Regimens and Durations for Grazoprevir-Elbasvir Patient Population Treatment Duration Genotype 1a: Treatment-nai ve or P/R experienced without baseline NS5A polymorphisms Genotype 1a: Treatment-nai ve or P/R-experienced with baseline NS5A polymorphisms* Genotype 1b: Treatment-nai ve or P/R-experienced EBR-GZR EBR-GZR + RBV EBR-GZR 12 weeks 16 weeks 12 weeks GT 4: Treatment-naïve EBR-GZR 12 weeks GT 4: PegIFN/RBV-Experienced EBR-GZR + RBV 16 weeks Grazoprevir/Elbasvir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
35 Retreatment Options for DDA- Experienced Patients Treating DAA Failures
36 Glecaprevir (NS3/4A)-Pibrentasvir (NS5A) MAVIRET Pangenotypic Coverage Previous DAA failures RBV free NS5B NS5A NS3
37 Glecaprevir-Pibrentasvir Health Canada Approved Aug 2017 Indication - Treatment-naïve patients genotypes 1-6 without cirrhosis and with compensated cirrhosis (Child-Pugh A) - HCV genotype 1 previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both Dosing: Three tablets orally once daily, with food (total daily dose of Glecaprevir 300 mg and Pibrentasvir 120 mg) Adverse Effects (AE): most common headache and fatigue Drug Interactions: GLE substrate of CYP 3A4, BCRP, P-gp, OATP1B1/3 Inhibits CYP3A4 (weak), UGT1A1, BCRP, P-gp, OATP1B1/3 PIB substrate of CYP 3A4, BCRP, P-gp Inhibits CYP3A4 (weak), UGT1A1, BCRP, P-gp, OATP1B1/3 Glecaprevir-Pibrentasvir [product monograph]. St-Laurent (QC): Abbvie Corporation, 2017.
38 Hepatology 2017;66(2):389-97; AASLD-IDSA. Updated 2017 Sep 21. Glecaprevir-Pibrentasvir Clinical Trials Study Genotype Treatment History Duration (weeks) N SVR12 Studies in Subjects without Cirrhosis >99% Endurance 1 1 TN + TE % Endurance 2 2 TN + TE >99% % Endurance 3 3 TN % Surveyor 2 Part % 3 TE % 2, 4 6 TN + TE % Surveyor 2 Part TN + TE % Studies in Subjects with Cirrhosis Expedition 1 1,2, 4 6 TN + TE % TN % Surveyor 2 Part 3 3 TE % Studies in Special Populations (with and without cirrhosis) Expedition TN + TE % Magellan 1 Part 2 1, 4 TE-NS5A and/or PI % %
39 SVR12 (%) MAGELLAN-1, PART 2 Randomized trial of Glecaprevir-Pibrentasvir for 12 or 16 weeks in HCV GT1- or GT4- infected patients with prior DAA failure, without cirrhosis or with compensated cirrhosis PI only NS5A only PI + NS5A n N G/P 12 weeks G/P 16 weeks SVR12 rate by prior DAA therapy Hepatology 2017;66(2):
40 Glecaprevir-Pibrentasvir Treatment Regimens Treatment-Naïve Patients HCV Genotype No Cirrhosis Treatment Duration Compensated Cirrhosis (Child-Pugh Class A) Genotype 1,2,3,4,5,6 8 weeks 12 weeks Glecaprevir-Pibrentasvir [product monograph]. St-Laurent (QC): Abbvie Corporation, 2017.
41 Glecaprevir-Pibrentasvir Treatment Regimens Treatment Experienced-Patients HCV Genotype 1, 2, 4, 5, or 6 1 Patients Previously Treated With a Regimen Containing: PEG + RIB +/- sofosbuvir (NS5B inhibitor) An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor An NS3/4A PI without prior treatment with an NS5A inhibitor No Cirrhosis Treatment Duration Compensated Cirrhosis (Child-Pugh Class A) 8 weeks 12 weeks 16 weeks 12 weeks 3 PEG + RIB +/- sofosbuvir (NS5B inhibitor) 16 weeks Glecaprevir-Pibrentasvir [product monograph]. St-Laurent (QC): Abbvie Corporation, 2017.
42 Sofosbuvir-Velpatasvir-Voxilaprevir VOSEVI Pangenotypic coverage Previous DAA failures RBV free NS5B NS3 NS5A
43 Sofosbuvir-Velpatasvir-Voxilaprevir Health Canada Approved Aug 2017 Indication -adult patients, without cirrhosis or with compensated cirrhosis, genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor Dosing: One tablet (400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir), taken orally, once daily with food Adverse Effects (AE): most common headache, fatigue, diarrhea, and nausea. Drug Interactions: Similar to Sof/Vel and Vox is a substrate of CYP 3A4, P-gp, BCRP and OATP 1B1/3 Also Inhibitor of P-gp, BCRP and OATP 1B1/3 Sofosbuvir-Velpatasvir-Voxilaprevir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
44 Sofosbuvir-Velpatasvir-Voxilaprevir POLARIS Phase 3 Trials in DAA experienced Pts STUDY PATIENTS REGIMEN SVR12 POLARIS-1 N= 415 GT 1 6 NS5A experienced NS5A & NS3 (32%) NS5A & NS5B (61%) NS5A (7%) 46% cirrhotic POLARIS-4 GT 1-4 non-ns5a experienced NS5B & NS3 (25%) NS5B (75%) 46% cirrhotic SOF/VEL/Vox (N = 263) Placebo (N = 152) 12 weeks SOF/VEL/VOX (N = 182) SOF/VEL(N = 151) 12 weeks 96% SOF/VEL/VOX SOF/VEL GT1a 98% 89% GT3 96% 85% N Engl J Med 2017;376:
45 Sofosbuvir-Velpatasvir-Voxilaprevir Treatment Regimens Adults Without Cirrhosis or With Compensated Cirrhosis (Child-Pugh A) HCV Genotype Without Cirrhosis or with Compensated Cirrhosis Patients Previously Treated with an HCV Regimen Containing: Duration Genotype 1,2,3,4,5,6 An NS5A inhibitor 12 weeks Genotype 1,2,3,4* Sofosbuvir without an NS5A inhibitor 12 weeks *US Labeling: indicated for genotype 1a and 3 as comparable SVR12 rates were observed in subjects with genotype 1b and 2 infection treated with Sof/Vel/Vox vs. Sof/Vel. Sofosbuvir-Velpatasvir-Voxilaprevir [product monograph]. In: e-cps. Ottawa (ON): Canadian Pharmacists Association, 2017
46 DAA Regimen Comparison at a Glance... DAA Regimen Genotype Trx Length Previous DAA TE Safety in CKD Safety in CP BC Pharma- Care SOF/VEL 1, 2, 3, 4, 5, 6 12 wks No EBR/GZR 1, 4, wks No GLE/PIB 1, 2, 3, 4, 5, wks Yes SOF/VEL/VOX 1, 2, 3, 4, 5, 6 12 wks Yes CKD: chronic kidney disease; CP BC: Child-Pugh class B or C; TE: treatment experienced; Trx: treatment T. Hussaini
47 Targets for HCV Elimination... Image credit: TUBS. Wikimedia Commons
48 HCV Cascade of Care in British Columbia as of Dec 31, 2012 EBioMedicine 2016; 12: ,906 24%
49 Towards HCV Elimination Scale up screening Target people at high risk of transmission (PWID, MSM, incarcerated) Scale up Treatment by removing treatment barriers Patient level barriers Structural barriers Removing restrictions for disease severity and treatment providers Harm reduction strategies in high risk population Opioid substitution Needle exchange & disposal programs Addiction 2018;113(3):545-63
50
51 AASLD-IDSA. Updated 2017 Sep 21.
52 Check DDIs prior to initiating DAAs!
53 The Future is Promising! Thank you for your attention... Ravidasvir/Sofosbuvir Kollewe J. The Guardian Apr 12. Available from: URL: hepatitis-c-cure-as-effective-as alternative. Image credit: Josep Lago, AFP, Getty Images
HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationEpclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationHighlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
December 16 Volume 12, Issue 12, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus From the 16 AASLD Liver Meeting A Review of Selected Presentations From the
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationONE REGIMEN, ALL GENOTYPES, 8 WEEKS
For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationUpdates on the AASLD/IDSA HCV Guidance
Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationHCV Pharmacology for All Clinicians
HCV Pharmacology for All Clinicians Disclosure I have nothing to disclose. Parya Saberi, PharmD, MAS Assistant Professor, UCSF Center for AIDS Prevention Studies Medical Management of HIV/AIDS and Hepatitis
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationUpdates in the Treatment of HCV
Updates in the Treatment of HCV Misty Miller, Pharm.D., BCPS, AAHIVP Associate Professor University of Oklahoma College of Pharmacy September 21 st, 2018 Overview HCV Review and Definitions HCV Genotypes
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationOutpatient Pharmacy Effective Date: August 15, 2014
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationTreating Hepatitis C in Patients with Advanced Renal Disease
Treating Hepatitis C in Patients with Advanced Renal Disease Seyed Moayed Alavian M.D. Professor of Medicine, Hepatologist alavian@thc.ir Hemodialysis Patients hemodialysis Preventive Strategies Strict
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationDisclosures. Lisa M. Chirch, MD, FIDSA has disclosed that she has served on advisory boards for Gilead Sciences and Melinta Therapeutics.
HEPATITIS C IN 2017 Lisa M. Chirch, M.D. Associate Professor of Medicine University of Connecticut Health Center A Local Performance Site of the New England AETC Disclosures Lisa M. Chirch, MD, FIDSA has
More informationNext generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos
Next generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos Associate Professor of Gastroenterology, Academic Department of Gastroenterology, National and Kapodistrian University
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Clinical Infectious Diseases IDSA FEATURES Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel a (See
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationA Practical Approach to HIV/HCV Co-infection
A Practical Approach to HIV/HCV Co-infection Focus on Drug-Drug Interactions Amy Hirsch Shumaker, PharmD, BCPS HIV/Hepatitis C Clinical Pharmacy Specialist Louis Stokes Cleveland VA Medical Center Andrea
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More informationMEDICATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C
MEDICATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C Annette Hewitt, ARNP, Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium CONFLICT OF INTEREST DISCLOSURE STATEMENT None. I will
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationOptimizing HCV Treatment Continuity and Outcomes
Optimizing HCV Treatment Continuity and Outcomes Empowering Pharmacists to Take Action Faculty Michelle T. Martin, PharmD, BCPS, BCACP Clinical Pharmacist University of Illinois Hospital and Health Sciences
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More information